The effects of 2-substituted oestrogen sulphamates on the growth of prostate and ovarian cancer cells

Journal of Steroid Biochemistry and Molecular Biology

Volumn 84, Issue 2-3, 2003, Pages 317-325

  Day, Joanna M ^a   Newman, Simon P ^a   Comninos, Alexander ^a   Solomon, Claire ^a   Purohit, Atul ^a   Leese, Matthew P ^b   Potter, Barry V L ^b   Reed, Michael J ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BATH   (United Kingdom)

Author keywords

2 Methoxyoestradiol; Ovarian cancer; Prostate cancer; Sulphamates

Indexed keywords

2 ETHYLESTRADIOL; 2 ETHYLESTRONE; 2 METHOXYESTRONE; 2 SUBSTITUTED ESTROGEN SULFAMATE; COLCHICINE; ESTROGEN DERIVATIVE; PACLITAXEL; PROTEIN BCL 2; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; CELL SHAPE; CONFERENCE PAPER; DRUG EFFECT; DRUG RESISTANCE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; IMMUNOBLOTTING; MITOSIS; OVARY CANCER; PHOSPHORYLATION; PROSTATE CANCER;

EID: 0037321660     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(03)00045-1     Document Type: Conference Paper

References (30)

1. 2/M phase and inhibits growth of human prostate cancer cells. Mol. Carcinog. 31:2001;111-124.
2. Edmondson R.J., Monaghan J.M. The epidemiology of ovarian cancer. Int. J. Gynecol. Cancer. 11:2001;423-429.
3. Oh W.K. Chemotherapy for patients with advanced prostate carcinoma. Cancer Suppl. 88:2000;3015-3021.
4. Robertson C.N., Roberson K.M., Padilla G.M., O'Brien E.T., Cook J.M., Kim C.S., Fine R.L. Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J. Natl. Cancer Inst. 88:1996;908-917.
5. du Bois A. Treatment of ovarian cancer. Eur. J. Cancer. 37:2001;S1-S7.
6. Kaye S.B. Future directions for the management of ovarian cancer. Eur. J. Cancer. 37:2001;S19-S23.
7. Wong K.K., Cheng R.S., Mok S.C. Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system. Biotechniques. 30:2001;670-675.
8. Zhu B.T., Conney A.H. Is 2-methoxyoestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res. 58:1998;2269-2277.
9. Klauber N., Parangi S., Flynn E., Hamel E., D'Amato R.J.D. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. 57:1997;81-86.
10. Fotsis T., Zhang Y., Pepper M.S., Adlercreutz H., Montesano R., Nawroth P.P., Schweigerer L. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature. 368:1994;237-239.
11. 2/M arrest and apoptosis in prostate cancer. Biochem. Biophys. Res. Commun. 285:2001;1259-1266.
12. MacCarthy-Morrogh L., Townsend P.A., Purohit A., Hejaz H.A.M., Potter B.V.L., Reed M.J., Packham G. Differential effects of estrone and estrone-3-O-sulphamate derivatives on mitotic arrest, apoptosis, and microtubule assembly in human breast cancer cells. Cancer Res. 60:2000;5441-5450.
13. Purohit A., Woo L.W.L., Barrow D., Hejaz H.A.M., Nicholson R.I., Potter B.V.L., Reed M.J. Non-steroidal and steroidal sulphamates: new drugs for cancer therapy. Mol. Cell. Endocrinol. 171:2001;129-135.
14. Purohit A., Hejaz H.A.M., Walden L., MacCarthy-Morrogh L., Packham G., Potter B.V.L., Reed M.J. The effect of 2-methoxyoestrone-3-O-sulphamate on the growth of breast cancer cells and induced mammary tumours. Int. J. Cancer. 85:2000;584-589.
15. Horoszewicz J.S., Leong S.S., Chu T.M., Wajsman Z.L., Friedman M., Papsidero L., Kim U., Chai L.S., Kakati S., Arya S.K., Sandberg A.A. The LNCaP cell line - a new model for studies on human prostatic carcinoma. Prog. Clin. Biol. Res. 37:1980;115-132.
16. Kaighn M.E., Narayan K.S., Ohnuki Y., Lechner J.F., Jones L.W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest. Urol. 17:1979;16-23.
17. Hamilton T.C., Young R.C., Ozols R.F. Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches. Semin. Oncol. 11:1984;285-298.
18. Behrens B.C., Hamilton T.C., Masuda H., Grotzinger K.R., Whang-Peng J., Louie K.G., Knutsen T., McKoy W.M., Young R.C., Ozols R.F. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res. 47:1987;414-418.
19. Okada M., Iwashita S., Koizumi N. Efficient general method for sulfamoylation of a hydroxyl group. Tetrahedron Lett. 41:2000;7047-7051.
20. Juliano R.L., Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta. 455:1976;152-162.
21. Cole S.P., Bhardwaj G., Gerlach J.H., Mackie J.E., Grant C.E., Almquist K.C., Stewart A.J., Kurz E.U., Duncan A.M., Deeley R.G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 258:1992;1650-1654.
22. Doyle L.A., Yang W., Abruzzo L.V., Krogmann T., Gao Y., Rishi A.K., Ross D.D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 95:1998;15665-15670.
23. Van Hattum A.H., Hoogsteen I.J., Schluper H.M., Maliepaard M., Scheffer G.L., Scheper R.J., Kohlhagen G., Pommier Y., Pinedo H.M., Boven E. Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity. Br. J. Cancer. 87:2002;665-672.
24. Van Hattum A.H., Pinedo H.M., Schluper H.M.M., Hausheer F.H., Boven E. New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer. Int. J. Cancer. 88:2000;260-266.
25. 6 does not induce P-glycoprotein-mediated multidrug resistance. Biomaterials. 21:2000;2203-2210.
26. Minko T., Paranjpe P.V., Qiu B., Lalloo A., Won R., Stein S., Sinko P.J. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells. Cancer Chemother. Pharmacol. 50:2002;143-150.
27. Attalla H., Makela T.P., Adlercreutz H., Andersson L.C. 2-Methoxyoestradiol arrests cells in mitosis without depolymerising tubulin. Biochem. Biophys. Res. Commun. 228:1996;467-473.
28. Zoubine M.N., Weston A.P., Johnson D.C., Campbell D.R., Banerjee S.K. 2-Methoxyestradiol-induced growth suppression and lethality in estrogen-responsive MCF-7 cells may be mediated by down regulation of p34cdc2 and cyclin B1 expression. Int. J. Oncol. 15:1999;639-646.
29. Attalla H., Westberg J.A., Andersson L.C., Adlercreutz H., Makela T.P. 2-Methoxyoestradiol-induced phosphorylation of Bcl-2: uncoupling from JNK/SAPK activation. Biochem. Biophys. Res. Commun. 247:1998;616-619.
30. Manfredi J.J., Parness J., Horwitz S.B. Taxol binds to cellular microtubules. J. Cell Biol. 94:1982;688-696.